Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745600 | 1.00 | HTT (0.58) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL6676325 | 0.87 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL26042832 | 0.87 | HTT (0.62) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL1531305 | 0.84 | HTT (0.58) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL1579202 | 0.79 | HTT (0.57) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL12429752 | 0.79 | HTT (0.53) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL1531395 | 0.79 | HTT (0.53) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL4705081 | 0.79 | HTT (0.53) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL1531391 | 0.79 | HTT (0.53) | HTTSMN1; SMN2LMNATDP1PKM | |
| SCHEMBL4374575 | 0.78 | HTT (0.51) | HTTSMN1; SMN2LMNATDP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114941015-B | Process for the manufacture of high mirror image selectivity secondary alcohols | 深圳艾欣达伟医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11773118-B2 | Methods of making high enantioselective secondary alcohols | OBI PHARMA, INC. (TW) | 2023-10-03 | — | — | US | disclosed |
| US-11773118-B2 | Methods of making high enantioselective secondary alcohols | OBI PHARMA, INC. (TW) | 2023-10-03 | — | — | US | disclosed |
| US-11773118-B2 | Methods of making high enantioselective secondary alcohols | OBI PHARMA, INC. (TW) | 2023-10-03 | — | — | US | disclosed |
| CN-114941015-A | Method for producing secondary alcohol with high mirror image selectivity | 深圳艾欣达伟医药科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-113474315-B | Method for producing secondary alcohol with high mirror image selectivity | 深圳艾欣达伟医药科技有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220106339-A1 | Methods of Making High Enantioselective Secondary Alcohols | OBI PHARMA, INC. (TW) | 2022-04-07 | — | — | US | disclosed |
| US-20220106339-A1 | Methods of Making High Enantioselective Secondary Alcohols | OBI PHARMA, INC. (TW) | 2022-04-07 | — | — | US | disclosed |
| CN-113474315-A | Method for producing secondary alcohol with high mirror image selectivity | 深圳艾欣达伟医药科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106339-A1 | Methods of Making High Enantioselective Secondary Alcohols | ADH5, OSTC, ADH1A | HTT 4824/4885SMN1; SMN2 3807/4885LMNA 4535/4885 |
| US-11773118-B2 | Methods of making high enantioselective secondary alcohols | ADH5, OSTC, ADH1A | HTT 4824/4885SMN1; SMN2 3807/4885LMNA 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.